Results 171 to 180 of about 930 (239)

CDK4/6 Inhibitors in the Management of Hormone Receptor‐Positive (HR+)/Human Epidermal Growth Factor Receptor 2‐Negative (HER2−) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
Evidence‐informed recommendations emphasize the integration of CDK4/6 inhibitors with endocrine therapy as a central component in the management of HR+/HER2− advanced breast cancer in Indonesia. Expanding access and facilitating integration within national treatment frameworks are crucial to improve outcomes and reduce disparities in care.
Sonar Soni Panigoro   +9 more
wiley   +1 more source

Genome‐wide association and interaction analysis for proliferative retinopathy in adults with type 2 diabetes born during famine: The DOLCE study in Ukraine

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose Proliferative diabetic retinopathy (PDR) is one of the leading causes of blindness in working‐age adults. We have previously shown that the risk of PDR is significantly elevated in individuals with intrauterine exposure to famine. However, the genetic mechanisms mediating this association remain unknown.
Olena Fedotkina   +7 more
wiley   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

open access: yesBritish Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk   +2 more
wiley   +1 more source

Functions of Glycosyl Phosphatidylinositols

open access: yes
David M. Rancour   +2 more
core   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

A comprehensive review of cancer‐induced cardiac wasting

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural cardiac remodelling, impaired contractile function and the development of ...
Alessia Lena   +5 more
wiley   +1 more source

Natural product‐derived TRPM7 channel inhibitors in neurological injury: Mechanisms, pharmacological potential and translational challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
Disruption of intracellular ionic homeostasis is a convergent pathological feature across diverse neurological injuries and disorders, including ischaemic and haemorrhagic stroke, hypoxic–ischaemic brain injury, traumatic brain injury, epilepsy and brain tumour.
Xinyang Zhang   +5 more
wiley   +1 more source

Dietary melatonin and its benefits on cardiovascular disease

open access: yesBritish Journal of Pharmacology, EarlyView.
Cardiovascular disease remains the leading cause of mortality globally, with a disproportionate burden in low‐ and middle‐income countries. Melatonin, a hormone primarily produced by the pineal gland, exhibits notable antioxidant, anti‐inflammatory and immunomodulatory properties that may confer cardiovascular benefits.
Karabo Tisane   +2 more
wiley   +1 more source

Evidence That the Protein Phosphatase Activity of PTEN Contributes to Embryonic Development and Tumor Suppression

open access: yesCancer Science, EarlyView.
Mice expressing only mutant PTEN Y138L, a protein which shows normal suppression of cellular AKT yet lacks protein phosphatase activity, die in utero, and heterozygous mice display a range of tumors. This indicates both the lipid and protein phosphatase activities of PTEN work together for normal tumor suppression and embryonic development.
Priyanka Tibarewal   +16 more
wiley   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

open access: yesCancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy